title: Metabonomics and drug development.
abstract: Metabolites as an end product of metabolism possess a wealth of information about altered metabolic control and homeostasis that is dependent on numerous variables including age, sex, and environment. Studying significant changes in the metabolite patterns has been recognized as a tool to understand crucial aspects in drug development like drug efficacy and toxicity. The inclusion of metabonomics into the OMICS study platform brings us closer to define the phenotype and allows us to look at alternatives to improve the diagnosis of diseases. Advancements in the analytical strategies and statistical tools used to study metabonomics allow us to prevent drug failures at early stages of drug development and reduce financial losses during expensive phase II and III clinical trials. This chapter introduces metabonomics along with the instruments used in the study; in addition relevant examples of the usage of metabonomics in the drug development process are discussed along with an emphasis on future directions and the challenges it faces.
authors: Pharmaceutical Analysis, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, O&N2 PB 923, Herestraat 49, 3000, Leuven, Belgium.
authors: Pranov
authors: P
authors: Ramana
authors: Erwin
authors: E
authors: Adams
authors: Patrick
authors: P
authors: Augustijns
authors: Ann
authors: A
authors: Van Schepdael
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006801:Humans; D055432:Metabolomics / Q000379:methods*; D013223:Statistics as Topic
chemical_list: D015415:Biomarkers